Novo Nordisk to acquire Prothena’s ATTR amyloidosis programme for $1.2bn
Danish pharma company Novo Nordisk has agreed to acquire Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme for a deal valued at $1.2bn. Under the terms